Linagliptin
Tsatanetsatane wa Zamalonda
Zogulitsa Tags
| Paketi Kukula | Kupezeka | Mtengo (USD) |
Dzina la Chemical:
8--[(3R)-3-aminopiperidin-1-yl]-7-(koma-2-yn-1-yl)-3- methyl-1--[(4-methylquinazolin-2-yl)methyl]-3 , 7-dihydro-1H-purine-2,6-dione
SMILES Kodi:
O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O
InChi kodi:
InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33 (23 (21 )34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2 ,1-3H3/t17-/m1/s1
InChi Key:
LTXREWYXXSTFRX-QGZVFWFLSA-N
Mawu ofunika:
Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0
Kusungunuka:Zosungunuka mu DMSO
Posungira:0 - 4 ° C kwa nthawi yochepa (masiku mpaka masabata), kapena -20 ° C kwa nthawi yaitali (miyezi).
Kufotokozera:
Linagliptin, yemwe amadziwikanso kuti BI-1356, ndi DPP-4 inhibitor yopangidwa ndi Boehringer Ingelheim pochiza matenda amtundu wachiwiri. Linagliptin (kamodzi patsiku) idavomerezedwa ndi US FDA pa Meyi 2, 2011 pochiza matenda amtundu wachiwiri. Ikugulitsidwa ndi Boehringer Ingelheim ndi Lilly.
Cholinga: DPP-4
